BridgeBio Pharma Inc (BBIO): Next-Year EPS Estimate 94.90%
As of 2026-10-16, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 94.90%. Featured in our EPS revision report on 2026-07-09.
On 2026-10-15, analyst consensus for BBIO's next-year EPS growth shifted from 95.14% to 94.90% — a negative change of 0.24 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 26.62%.
What's Driving This
Analysts have revised next-year EPS growth estimates upward on net since an initial cut, with the current estimate at 103.20% reflecting a positive structural shift. The upgrade appears connected to recent acoramidis data in ATTR-CM, including evidence of cardiac structural disease reversal and reduced hospitalizations. This clinical momentum has continued with new presentations and a Phase 3b/4 trial launch, supporting further estimate gains.
Generated 2026-09-09 from news as of 2026-09-09
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 94.90%
- EPS growth this year
- 26.62%
- EPS next quarter (est)
- -$0.57
- Last price
- $66.39
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-10-16 | 94.90% | 26.62% | -$0.57 | $66.39 |
| 2026-10-15 | 94.90% | 26.62% | -$0.57 | $67.13 |
| 2026-10-14 | 95.14% | 26.64% | -$0.56 | $64.94 |
| 2026-10-13 | 97.61% | 26.70% | -$0.58 | $63.30 |
| 2026-10-12 | 101.21% | 26.91% | -$0.59 | $65.75 |
| 2026-10-11 | 102.52% | 26.27% | -$0.61 | $65.35 |
| 2026-10-10 | 102.52% | 26.27% | -$0.61 | $65.35 |
| 2026-10-09 | 102.52% | 26.27% | -$0.61 | $65.35 |
| 2026-10-08 | 102.52% | 26.27% | -$0.61 | $65.04 |
| 2026-10-07 | 102.52% | 26.27% | -$0.61 | $66.50 |
| 2026-10-06 | 102.52% | 26.27% | -$0.61 | $66.96 |
| 2026-10-05 | 102.31% | 26.28% | -$0.61 | $66.14 |
| 2026-10-04 | 102.31% | 26.28% | -$0.61 | $67.25 |
| 2026-10-03 | 102.32% | 26.28% | -$0.61 | $67.25 |
| 2026-10-02 | 102.32% | 26.28% | -$0.61 | $67.25 |
| 2026-10-01 | 102.32% | 26.27% | -$0.61 | $66.91 |
| 2026-09-30 | 102.32% | 26.27% | -$0.61 | $65.80 |
| 2026-09-29 | 102.32% | 26.27% | -$0.61 | $65.97 |
| 2026-09-28 | 103.00% | 26.38% | -$0.61 | $66.61 |
| 2026-09-27 | 103.05% | 26.39% | -$0.61 | $65.57 |
| 2026-09-25 | 103.05% | 26.39% | -$0.61 | $65.57 |
| 2026-09-24 | 103.05% | 26.39% | -$0.61 | $66.28 |
| 2026-09-23 | 103.05% | 26.39% | -$0.61 | $65.71 |
| 2026-09-22 | 103.05% | 26.39% | -$0.61 | $69.23 |
| 2026-09-21 | 103.05% | 26.39% | -$0.61 | $66.58 |
| 2026-09-20 | 103.05% | 26.39% | -$0.61 | $66.61 |
| 2026-09-18 | 103.05% | 26.39% | -$0.61 | $66.61 |
| 2026-09-17 | 103.05% | 26.39% | -$0.61 | $67.31 |
| 2026-09-16 | 103.05% | 26.39% | -$0.61 | $68.30 |
| 2026-09-15 | 103.05% | 26.39% | -$0.61 | $68.39 |
Reports Featuring BBIO
Recent News
- Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CMGlobeNewswire
- BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CMGlobeNewswire
- Hershey Company Upgraded, Toast, Inc. Downgraded: Updated Rankings on Top Blue-Chip StocksInvestorPlace
- BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026GlobeNewswire
- Exelixis, Valaris, and 3 More Stocks See Action From Activist InvestorsBarrons.com
- BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder BaseGlobeNewswire
- BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing ShareholderGlobeNewswire
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- BridgeBio Pharma Inc (BBIO) (Q2 2026) Earnings Call Highlights: Attruby Surges 211% as Pipeline ...GuruFocus.com
- BridgeBio Pharma, Inc. Q2 2026 Earnings Call SummaryMoby
Screen Performance
Aggregate stats across all 2082 tickers our top-EPS-revision screen has flagged over the past 198 days.
- Median return since detection
- -3.0%
- % of tickers in the green
- 43%
- Median return on winners
- +21.5%
- Large revisions captured
- 1886
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is BridgeBio Pharma Inc's next-year EPS growth estimate?▾
As of 2026-10-16, BridgeBio Pharma Inc (BBIO) has a next-year EPS growth estimate of 94.90%, based on analyst consensus.
When was the latest EPS estimate revision for BBIO?▾
The most recent revision occurred on 2026-10-15, when analysts adjusted the next-year EPS growth estimate from 95.14% to 94.90%.
What sector and industry does BridgeBio Pharma Inc belong to?▾
BridgeBio Pharma Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. BBIO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. BridgeBio Pharma Inc (BBIO) appears here because it was detected by our daily top-EPS-revision-performer screen.